SCHEMBL3502201

SCHEMBL3502201

COc1ccc(-c2ccc(Br)c(OC)c2)c(N)c1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 5/20 0.51
MEN1 O00255 2/20 0.51
MAPT P10636 2/20 0.51
THRB P10828 2/20 0.51
KMT2A Q03164 2/20 0.51
CYP3A4 P08684 4/20 0.47
CYP1A2 P05177 2/20 0.47
CYP2D6 P10635 2/20 0.47
CYP2C9 P11712 2/20 0.47
CYP2C19 P33261 2/20 0.47
CYP1A1 P04798 1/20 0.47
CYP2E1 P05181 1/20 0.47
CYP2C8 P10632 1/20 0.47
CYP2A6 P11509 1/20 0.47
CYP4B1 P13584 1/20 0.47
CYP2B6 P20813 1/20 0.47
CYP3A5 P20815 1/20 0.47
CYP2A7 P20853 1/20 0.47
CYP3A7 P24462 1/20 0.47
CYP2F1 P24903 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30839719 0.83 ALDH1A1 (0.70) ALDH1A1MEN1MAPTTHRBKMT2A
SCHEMBL30839723 0.83 ALDH1A1 (0.70) ALDH1A1MEN1MAPTTHRBKMT2A
SCHEMBL30839720 0.83 ALDH1A1 (0.70) ALDH1A1MEN1MAPTTHRBKMT2A
SCHEMBL27185990 0.83 ALDH1A1 (0.70) ALDH1A1MEN1MAPTTHRBKMT2A
SCHEMBL6361648 0.81 CYP3A4 (0.52) ALDH1A1MEN1MAPTTHRBKMT2A
SCHEMBL13952628 0.80 TUBB4A (0.55) ALDH1A1MEN1MAPTTHRBKMT2A
SCHEMBL227503 0.80 GSTP1 (0.62) ALDH1A1MEN1MAPTTHRBKMT2A
SCHEMBL2888669 0.79 ALDH1A1 (0.45) ALDH1A1MEN1MAPTKMT2ACYP3A4
SCHEMBL29558143 0.78 CA12 (0.62) ALDH1A1MEN1MAPTTHRBKMT2A
SCHEMBL14127541 0.78 CA12 (0.62) ALDH1A1MEN1MAPTTHRBKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8927569-B2 Macrocyclic compounds as antiviral agents MERCK SHARP & DOHME CORP. (US) 2015-01-06 US disclosed
EP-2178902-B1 MACROCYCLIC COMPOUNDS AS ANTIVIRAL AGENTS ANGELETTI P IST RICHERCHE BIO (IT) 2012-11-28 EP disclosed
US-20100183551-A1 Macrocyclic Compounds As Antiviral Agents MERCK SHARP & DOHME LLC 2010-07-22 US disclosed
EP-2178902-A1 MACROCYCLIC COMPOUNDS AS ANTIVIRAL AGENTS Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.P.A. (IT) 2010-04-28 EP disclosed
WO-2009010804-A1 MACROCYCLIC COMPOUNDS AS ANTIVIRAL AGENTS ISTITUTO DI RICERCHE DI BIOLOGIA MOLECOLARE P. ANGELETTI S.P.A. (IT) 2009-01-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100183551-A1 Macrocyclic Compounds As Antiviral Agents ZC3HAV1, RNASE1, RRP1B ALDH1A1 1764/4885MEN1 2523/4885MAPT 4532/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.